Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9502972 | 0.84 | AGXT (0.60) | AGXTALDH1A1MAOBGAAKMT2A | |
| SCHEMBL30230126 | 0.83 | TAAR1 (0.57) | ACHEDRD2DRD4DRD3POLB | |
| SCHEMBL7408051 | 0.83 | TAAR1 (0.57) | ACHEDRD2DRD4DRD3POLB | |
| SCHEMBL27465 | 0.82 | DRD2 (0.62) | ACHEDRD2DRD4DRD3POLB | |
| SCHEMBL10511421 | 0.82 | ACHE (0.60) | ACHEDRD2DRD4ALDH1A1MAOB | |
| SCHEMBL29381067 | 0.82 | DRD2 (0.62) | ACHEDRD2DRD4DRD3POLB | |
| SCHEMBL10085645 | 0.82 | DRD2 (0.58) | ACHEDRD2DRD4DRD3POLB | |
| SCHEMBL6846945 | 0.80 | DRD2 (0.57) | DRD2DRD4DRD3POLBTDP1 | |
| SCHEMBL11674802 | 0.80 | DRD2 (0.66) | ACHEDRD2DRD4DRD3TDP1 | |
| Hydrochloric Acid SCHEMBL10555508 | 0.80 | ACHE (0.58) | ACHEDRD2DRD4ALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-8895680-B2 | Redox curing-type nonaqueous curable composition | KURARAY NORITAKE DENTAL INC. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20100240798-A1 | REDOX-CURING TYPE NONAQUEOUS CURABLE COMPOSITION | KURARAY MEDICAL INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-1780223-B1 | REDOX CURING-TYPE NONAQUEOUS CURABLE COMPOSITION | KURARAY MEDICAL INC (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20080081889-A1 | Free radical monomers, organic peroxide and powdered water soluble reducing compound; high adhesive strength against wetting material; teeth and bone restoration | KURARAY MEDICAL INC. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1780223-A1 | REDOX CURING-TYPE NONAQUEOUS CURABLE COMPOSITION | Kuraray Medical Inc. (JP) | 2007-05-02 | — | — | EP | disclosed |
| US-5395925-A | Dyeing | SANDOZ LTD. (CH) | 1995-03-07 | — | — | US | disclosed |
| US-5227478-A | Textile dyes | SANDOZ LTD. (CH) | 1993-07-13 | — | — | US | disclosed |
| EP-0051559-A1 | Basic and/or cationic azo compounds free from sulfonic-acid groups | SANDOZ AG (CH) | 1982-05-12 | — | — | EP | disclosed |
| US-4129736-A | FIBER-REACTIVE | CIBA-GEIGY CORPORATION (US) | 1978-12-12 | — | — | US | disclosed |
| US-4079051-A | 4-Halogeno-s-triazin-2-yl-phosphoramide acid containing reactive dyestuffs | CIBA-GEIGY CORPORATION (US) | 1978-03-14 | — | — | US | disclosed |
| US-4033944-A | Fibre-reactive hydroxycycloalkenyl-halo triazinyl containing dyestuffs | CIBA-GEIGY CORPORATION (US) | 1977-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240798-A1 | REDOX-CURING TYPE NONAQUEOUS CURABLE COMPOSITION | LPO, CDH1, GPX4 | ACHE 1258/4885DRD2 971/4885DRD4 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.